Innovative Cell Therapy Immusoft specializes in advanced cell therapies that leverage the patient’s own B cells to deliver long-lasting therapeutic proteins, positioning it as a leader in personalized medicine solutions for rare diseases.

Strategic Collaborations Partnerships such as with Takeda, focusing on crossing the blood-brain barrier, present opportunities to expand into neurometabolic disorder markets and leverage joint R&D efforts to accelerate therapy development.

Recent Data Demonstrations With recent presentations at ASGCT 2025 showcasing positive clinical trial results, there is a compelling opportunity to engage with biotech and healthcare organizations interested in innovative gene and cell therapies.

Funding and Growth Potential Having secured $25 million in funding and generating revenues between one to ten million dollars, Immusoft demonstrates financial stability and growth potential that can support expanded sales outreach and partnership development.

Technology Platform Advantage The proprietary Immune System Programming platform offers a unique selling proposition for partners seeking to develop durable, personalized treatments, making it a promising target for licensing, collaborations, or joint venture opportunities.